| Malignant gliomas in adults PY Wen, S Kesari New England Journal of Medicine 359 (5), 492-507, 2008 | 4642 | 2008 |
| Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group PY Wen, DR Macdonald, DA Reardon, TF Cloughesy, AG Sorensen, ... Journal of clinical oncology 28 (11), 1963-1972, 2010 | 3638 | 2010 |
| Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma HS Friedman, MD Prados, PY Wen, T Mikkelsen, D Schiff, LE Abrey, ... Journal of clinical oncology 27 (28), 4733-4740, 2009 | 2752 | 2009 |
| AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients TT Batchelor, AG Sorensen, E di Tomaso, WT Zhang, DG Duda, ... Cancer cell 11 (1), 83-95, 2007 | 2023 | 2007 |
| Exciting new advances in neuro‐oncology: the avenue to a cure for malignant glioma EG Van Meir, CG Hadjipanayis, AD Norden, HK Shu, PY Wen, JJ Olson CA: a cancer journal for clinicians 60 (3), 166-193, 2010 | 1590 | 2010 |
| Epidemiology of brain metastases L Nayak, EQ Lee, PY Wen Current oncology reports 14, 48-54, 2012 | 1138 | 2012 |
| Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors MJ Glantz, BF Cole, PA Forsyth, LD Recht, PY Wen, MC Chamberlain, ... Neurology 54 (10), 1886-93, 2000 | 964 | 2000 |
| Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence AD Norden, GS Young, K Setayesh, A Muzikansky, R Klufas, GL Ross, ... Neurology 70 (10), 779-787, 2008 | 940 | 2008 |
| Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial DB Keskin, AJ Anandappa, J Sun, I Tirosh, ND Mathewson, S Li, ... Nature 565 (7738), 234-239, 2019 | 924 | 2019 |
| Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma TF Cloughesy, AY Mochizuki, JR Orpilla, W Hugo, AH Lee, TB Davidson, ... Nature medicine 25 (3), 477-486, 2019 | 871 | 2019 |
| Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib PG Richardson, H Briemberg, S Jagannath, PY Wen, B Barlogie, ... J Clin Oncol 24 (19), 3113-3120, 2006 | 756 | 2006 |
| Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases E Alexander III, TM Moriarty, RB Davis, PY Wen, HA Fine, PM Black, ... JNCI: Journal of the National Cancer Institute 87 (1), 34-40, 1995 | 747 | 1995 |
| Glioma M Weller, W Wick, K Aldape, M Brada, M Berger, SM Pfister, R Nishikawa, ... Nature reviews Disease primers 1 (1), 1-18, 2015 | 726 | 2015 |
| Response assessment criteria for brain metastases: proposal from the RANO group NU Lin, EQ Lee, H Aoyama, IJ Barani, DP Barboriak, BG Baumert, ... The lancet oncology 16 (6), e270-e278, 2015 | 675 | 2015 |
| Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600–mutant anaplastic thyroid cancer V Subbiah, RJ Kreitman, ZA Wainberg, JY Cho, JHM Schellens, JC Soria, ... Journal of Clinical Oncology 36 (1), 7, 2018 | 654 | 2018 |
| Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review L Rogers, I Barani, M Chamberlain, TJ Kaley, M McDermott, J Raizer, ... Journal of neurosurgery 122 (1), 4-23, 2015 | 583 | 2015 |
| Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non–small cell lung cancer, and other solid tumors A Patnaik, LS Rosen, SM Tolaney, AW Tolcher, JW Goldman, L Gandhi, ... Cancer discovery 6 (7), 740-753, 2016 | 581 | 2016 |
| Immunotherapy response assessment in neuro-oncology: a report of the RANO working group H Okada, M Weller, R Huang, G Finocchiaro, MR Gilbert, W Wick, ... The Lancet Oncology 16 (15), e534-e542, 2015 | 575 | 2015 |
| Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas HA Fine, WD Figg, K Jaeckle, PY Wen, AP Kyritsis, JS Loeffler, VA Levin, ... Journal of Clinical Oncology 18 (4), 708-708, 2000 | 571 | 2000 |
| Phase II study of cediranib, an oral pan–vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma TT Batchelor, DG Duda, E di Tomaso, M Ancukiewicz, SR Plotkin, ... Journal of Clinical Oncology 28 (17), 2817, 2010 | 542 | 2010 |
Timothy CloughesyUCLA在 mednet.ucla.edu 的电子邮件经过验证
